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ABSTRACT 41 
Purpose: To determine differences in key tear film cytokines between mild and severe cases 42 
of Acanthamoeba Keratitis (AK) and control contact lens (CL) wearers. 43 
Methods: This was a prospective study of CL wearers with AK attending Moorfields Eye 44 
Hospital (MEH) and control CL wearers from the Institute of Optometry, London. Basal tear 45 
specimens were collected by 10ul capillary tubes (Blaubrand intraMARK, Wertheim, 46 
Germany) and tear protein levels were measured with a multiplex magnetic bead array 47 
(Luminex 100, Luminex Corporation, Austin, TX) for cytokines IL-1β, IL-6, IL-8, IL-10, IL-17A, 48 
IL-17E, IL-17F, IL-22, and IFNγ and with ELISA (Abcam, Cambridge, UK) for CXCL2. Severe 49 
cases of AK were defined as having active infection for over 12 months and at least one severe 50 
inflammatory event.  51 
Results: One hundred and thirty two tear samples were collected from a total of 61 cases (15 52 
severe and 46 mild-moderate) and 22 controls. IL-8, part of the TLR4 cytokine cascade, was 53 
found to be expressed at a detectable level more often in cases of AK compared to control CL 54 
wearers (p=0.003), and in higher concentrations in severe compared to milder forms of the 55 
disease (z=-2.35). IL-22, part of the IL-10 family, and a proinflammatory Th17 cytokine, was 56 
detected more often in severe compared to milder forms of AK (p<0.02).  57 
Conclusion: Profiling Acanthamoeba Keratitis patients during disease shows differences in 58 
cytokine levels between severe and milder disease that may inform clinical management. The 59 
TLR4 and IL-10/Th17 inflammatory pathways should be included in further investigations of 60 
this disease. 61 
62 
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INTRODUCTION 63 
Acanthamoeba Keratitis (AK) is one of the most severe forms of corneal infection, with over 64 
90% of cases occurring in contact lens (CL) wearers.1 Vision loss occurs in 33% of patients, 65 
with corneal transplantation required in around 26%.2 Recent reports, and case monitoring at 66 
our centre, show that the numbers of AK cases are increasing.3, 4 AK generally affects a young 67 
and otherwise healthy group of individuals5 in whom lifetime disability costs are high. As well 68 
as the long term effects, such as decreased quality of life, and loss of productivity due to 69 
reduced vision, there are significant short term costs to sufferers and carers, such as loss of 70 
wages and distress, in addition to symptoms such as severe pain and light sensitivity 71 
experienced by sufferers.6 72 
Some complications associated with CLs are somewhat controlled by the release of tear 73 
inflammatory molecules, such as giant papillary conjunctivitis which is characterized by altered 74 
levels of eotaxin7 or corneal neovascularization which is mediated by vascular endothelial 75 
growth factor (VEGF).8 Moreover, it has been shown that CL wearers with CL-induced acute 76 
red eye present higher concentrations of IL-8 than healthy subjects9. Others10-13 have indicated 77 
altered levels of tear cytokines such as interleukin (IL)-6, IL-8 and epidermal growth factor 78 
(EGF) during CL wear. However, to this day little is known about the tear inflammatory 79 
mediation in AK. Profiling AK patients during disease could show differences in cytokine levels 80 
between severe and milder disease that may inform clinical management.  81 
The aim of this study is to determine the differences in cytokine levels in CL-wearing patients 82 
with AK compared to CL wearers without the disease. A secondary goal is to investigate 83 
differences in cytokine levels between patients with severe forms of AK and those with mild-84 
moderate forms of this infection 85 
MATERIALS AND METHODS 86 
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This was a prospective case control study of CL wearers with AK attending Moorfields Eye 87 
Hospital (MEH) and control CL wearers from the Institute of Optometry, London. The research 88 
protocol adhered to the tenets of the Declaration of Helsinki and was approved by the local 89 
ethics committee. Written informed consent was obtained from all participants. 90 
Participants 91 
Severe cases of AK were defined as having active infection for over 12 months and having 92 
had at least one severe inflammatory event such as scleritis, persistent non-healing defect (for 93 
14 days or more) and/or pupil paralysis. Mild-moderate cases had recurrent disease in the 94 
absence of severe inflammatory events or disease that required active treatment for less than 95 
and up to 12 months. 96 
Tear sample collection 97 
Samples were collected from AK patients at follow-up visits during their treatment on a 98 
convenience basis depending on the flow of the clinic visits. Collection times varied between 99 
10am and 4pm. Samples were collected from the affected eye only. For bilateral cases, the 100 
worst affected eye was sampled.   101 
Samples were collected from control CL wearers at the conclusion of routine aftercare 102 
appointments at the Institute of Optometry. Lenses may or may not have been worn according 103 
to the patient preference at the end of the appointment. So as to not affect the equilibrated 104 
tear milieu, that status remained for tear collection. For these control CL wearers, samples 105 
were collected from the right eye, and switched to the left should no sample be obtained from 106 
the right eye. In monocular wearers, the eye sampled was the CL wearing eye. 107 
Tear samples for both AK cases and controls were basal tear specimens collected by 10ul 108 
capillary tubes (Blaubrand intraMARK, Wertheim, Germany) and stored in 109 
ethylenediaminetetraacetic acid (EDTA) coated 0.5ml Eppendorf tubes. Following collection, 110 
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the samples were kept cold using a standard cool box and ice packs. Upon delivery to the 111 
laboratory on the same day, the samples were centrifuged at 1,600rpm for 5 minutes. The 112 
cell-free supernatant was then pipetted into clean EDTA coated 0.5ml Eppendorf tubes and 113 
stored at -80°C prior to analysis. 114 
Analysis of tear molecules 115 
Cytokines IL-1β, IL-6, IL-8, IL-10, IL-17A, IL-17E, IL-17F, IL-22, interferon (IFNγ) and 116 
chemokine (C-X-C motif) ligand 2 (CXCL2) were chosen for analysis based on established 117 
and hypothesised inflammatory pathways in AK. Tear protein levels were measured with a 118 
multiplex bead array using the Luminex based platform (Luminex 100, Luminex Corporation, 119 
Austin, TX) for all analytes apart from CXCL2. CXCL2 was measured with an enzyme-linked 120 
immunosorbent assay (ELISA, Abcam, Cambridge, UK) as this protein was not compatible 121 
with the chosen Luminex range of targets.  122 
Samples were diluted with the respective kit reagent depending on the sample volume and 123 
normalised for analysis. Standard curves using duplicate known dilutions were generated for 124 
the Luminex and ELISA analysis. Luminex data were analysed with the instrument software 125 
and raw scores of the ELISA optical density were converted to concentrations in Excel 2010 126 
(Microsoft). Concentrations lower than the detectable limits were labelled as not detectable 127 
(ND). Final concentrations above the minimum detectable limit were adjusted for the dilution 128 
factor. 129 
Data analysis 130 
Statistics were analysed using Graphpad.com/online calculator and Microsoft Excel 2010 131 
software. 132 
Differences between cases and controls and between severe and mild-moderate cases were 133 
determined as follow: Fishers exact test was performed to determine the proportions of 134 
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detectable samples and Mann-Whitney U test was used for the sample quantities over the 135 
detectable levels.  136 
P values less than or equal to 0.05 were considered statistically significant. 137 
RESULTS 138 
One hundred and thirty two tear samples were collected from a total of 61 AK cases (15 severe 139 
and 46 mild-moderate) and 22 controls. There were no differences in gender distribution 140 
between case and control groups (p=0.06), however significant differences in age were found 141 
between the groups (p<0.001). In addition, there were more daily disposable wearers in the 142 
control group compared to the AK cases (p=0.02). Descriptive data detailing age, gender and 143 
lens type, are shown in Table 1.  144 
Levels of IL-6, IL-8, IL-22 and IL-17E were readily detectable. The levels of IFNy, IL-17F, IL-145 
17A, IL-10, IL-27 and IL-1β were below the minimum detectable limit for all case and control 146 
samples.  The proportion of non detectable (ND) samples for each protein are detailed in Table 147 
2. 148 
Cases vs. controls 149 
Figure 1 shows the proportion of cytokines for the cases and controls for each of the molecules 150 
for which there was more than 1 positive sample (IL-1 β was detectable in only one sample, 151 
and was considered “non detectable” for this study). There were more samples with detectable 152 
levels of IL-8 in the cases compared to the controls (p=0.003). Almost half of the tear 153 
specimens in both groups had detectable levels of IL-22, whereas IL-6 and IL-17E showed 154 
very low frequencies of positivity. The one control with a positive sample for IL-6 was not the 155 
same control that was the only control sample positive for IL-17E. There was no difference 156 
between the CXCL2 levels for cases and controls with more than 75% of tear specimens 157 
yielding detectable quantities of this molecule (cases 56/67, 84% and controls, 10/13, 77%). 158 
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Figures 2-5 show the concentrations of IL-6, IL-8, IL-22, and IL-17E, respectively in tears of 159 
individual cases (by visit) and individual controls that measured above detectable limits by 160 
Luminex. Figure 6 shows the concentrations CXCL2 in tears of individual cases (by visit) and 161 
individual controls that measured above detectable limits by ELISA. There was no difference 162 
between the median concentration of IL-8, IL-22 and CXCL2 in tears of cases and controls 163 
(z=-0.57, z=0.97 and Z=0.05 respectively). Only one control sample was positive for IL-6 and 164 
IL-17E and so Mann-Whitney U Test could not be performed. 165 
Severe vs. mild-moderate cases 166 
Figure 7 shows the proportions of detectable protein samples (IL-8, IL-22, IL-6 and IL-17E) 167 
investigated with Luminex for severe compared to mild-moderate cases. IL-22 was less likely 168 
to be detected amongst the mild-moderate cases compared to the severe cases of AK 169 
(p=0.02), however there was no difference between mild-moderate cases and severe cases 170 
for the proteins, IL-8, IL-6 and IL-17E (p=0.48, p=0.27 and p=1.0 respectively). There was also 171 
no difference in CXCL2 levels between the severe and moderate/mild cases (23/29, 79.3% 172 
compared to 33/38, 86.8%, p=0.41) 173 
Table 3 shows the median tear protein concentrations for severe compared to the mild-174 
moderate samples. There was a higher level of IL-8 detectable in the tears of severe cases 175 
compared to the mild-moderate cases of this infection (z=-2.31), however there was no 176 
difference between tear protein levels of IL-22, IL-6, IL-17E and CXCL2).  177 
DISCUSSION 178 
The present study was the first to examine the cytokine levels in patients with mild compared 179 
to more severe AK, and compare these to control CL wearers. This study has highlighted IL-180 
8 as a key molecule in the AK inflammatory response, and there is also some evidence for 181 
cell mediated inflammatory response involving the IL-17 pathway, via IL-22. 182 
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IL-8 was found to be expressed at a detectable level measured by Luminex more often in 183 
cases of AK compared to control CL wearers, and in higher concentrations in more severe 184 
compared to milder forms of the disease. IL-8 is a key inflammatory chemokine that mobilises 185 
and activates neutrophils.7 Neutrophils are essential components of the early inflammatory 186 
response to Acanthamoeba.8 Furthermore, IL-8 is part of the toll like receptor 4 (TLR-4) 187 
cascade which initiates the cytokine response in AK.9 IL-8 also promotes angiogenesis in the 188 
eye7 and further characterisation of patients that develop neovascularisation in AK may reveal 189 
differences in levels that may predict patients who go on to develop this complication, and 190 
more targeted management such as frequent topical steroids may be advocated in these 191 
cases. Neovascularisation is a contraindicated in corneal transplant candidates, often the last 192 
resort to significantly improve vision in AK patients. Keratoplasty is required for visual 193 
rehabilitation in around 12% of AK cases.2  194 
IL-22, part of the IL-10 family, and a proinflammatory Th17 cytokine,10 was detected more 195 
often in severe compared to milder forms of AK. IL-22 may prolong the inflammatory response 196 
and, in severe forms of disease, this may be beneficial to control infection but may also be 197 
involved in tissue destruction due to inflammation. 198 
Most of the IL-17 cytokines were not detected in levels high enough to be measured in the 199 
tears in these subjects using Luminex technology. Since multiplex bead arrays are well 200 
established as being one of the more sensitive methods of detection for low levels of analytes, 201 
the specimens with no detectable levels were presumed negative. It may be useful to compare 202 
the IL-17E cytokine, which was expressed by a small number of cases and one control, using 203 
ELISA, in another cohort of samples. Like IL-22, IL-17 has been implicated in chronic 204 
inflammatory conditions11 and IL-17A has recently been shown to be protective against 205 
Acanthamoeba keratitis severity in a mouse model.12 This contrasts with keratitis caused by 206 
Herpes Simplex Virus and Pseudomonas where IL-17A is associated with an increased 207 
corneal inflammatory response.13-15. IL-17A is known as a “double sword” agent; in some 208 
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circumstances it protects the host and in others, it results in chronic inflammation and tissue 209 
damage.16) IL-17A both initiates and activates neutrophils and is also produced by 210 
neutrophils.17 Recently, a novel population of neutrophils were characterized, that are capable 211 
of autocrine IL-17A activity, which leads to increased death of fungal hyphae in a murine model 212 
of Aspergillus corneal infection.18   213 
CXCL2 (also known as macrophage inflammatory protein 2-alpha, MIP2-α) appears to be 214 
constitutively expressed in AK cases and control CL wearers and not up- or down-regulated 215 
in this disease. MIP2 has been shown to be important in animal models of AK.19 Animal models 216 
of disease do not exhibit the severe inflammatory complications of AK, such as scleritis 5, and 217 
inflammatory pathways may vary somewhat between humans and animal models.  218 
IL-6, a proinflammatory cytokine with several functions, was only detected in one control 219 
sample; either this study did not have enough power to show differences between cases and 220 
controls or IL-6 is not important in the inflammatory response in this disease. Furthermore it is 221 
possible that there is a defect in IL-6 at the protein level. Our group has found that single 222 
nucleotide polymorphisms (SNP) of IL-6 genes are implicated in the susceptibility and severity 223 
of bacterial keratitis in CL wearers.20 IL-6 is a key player in the IL-22 and IL-17 pathways11 and 224 
it would be prudent to further investigate this protein as a candidate in future immunological 225 
analysis in AK. 226 
Cytokine and chemokine profiles correlate with several inflammatory anterior eye disease 227 
states such as dry eye,21-24 allergic eye disease,25, 26 the autoimmune condition, Sjogren’s 228 
syndrome,27-29 vernal keratoconjunctivitis30 and ocular rosacea.31 Two studies have 229 
highlighted tear protein profiles associated with bacterial32 and fungal keratitis.33  230 
In bacterial keratitis, cytokines and chemokines are upregulated in both the affected and 231 
contralateral eye, and these changes have been correlated with cellular changes imaged on 232 
the ocular surface 32. Specifically, IL-1β, IL-6 and IL-8 were elevated in the ‘infected’ tears 233 
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compared to non-affected controls. Changes were also found in the contralateral eye of 234 
bacterial keratitis patients, namely the upregulation of chemokine ligand 2 (CCL-2), IL-10 and 235 
IL-17a. TREM-1 was also elevated in both the affected and contralateral eyes. Changes in 236 
tear cytokines were correlated with dendritic cell and sub-basal nerve fibre presence and 237 
morphology, as follows; tear concentrations of the proinflammatory cytokines, IL-1B, IL-6, IL-238 
8 and IL-17a were positively correlated with dendritic cell density, and IL-1B, IL-6, IL-8 and 239 
TREM-1 were inversely correlated with sub-basal nerve density. 240 
Proteomic analyses have been used in an Indian study of fungal keratitis patients compared 241 
to controls to examine differences between tear proteins. Seven protein levels varied between 242 
the cases and controls: Prolactin inducible protein and serum albumin precursor were up 243 
regulated in the infected samples; Cystatin S precursor, cystatin SN precursor, cystatin, and 244 
human tear lipocalin were downregulated in the infected samples; glutaredoxin-related protein 245 
was found only in the infected samples33. 246 
Concentrations of the following cytokines for all subjects in this study fell below the detectable 247 
limit for IFNγ, IL-10, IL-1β, IL-27 as well as IL-17F and IL-17A. Cross reactivity of the 248 
antibodies and/or poor sensitivity of the array are unlikely to be implicated since bead-based 249 
Luminex technology is one of the most sensitive assays available and has successfully 250 
allowed detection of cytokines in tear fluids.34 It is possible that these cytokines were masked 251 
from detection in the tear specimens due to a build-up of protein and debris at the ocular 252 
surface. Alternatively, these cytokines might not be involved in this disease but, until a larger 253 
cohort of specimens and controls is investigated, this cannot be assumed. 254 
The differences in cytokine levels found in this study may be due to the effects of the disease 255 
on the immune system and/or due to differences in the individual’s immune profile at the gene 256 
level. Being such a rare disease, it is impossible to conduct a prospective study and compare 257 
cytokine levels before and during AK disease, however future studies that assess variations 258 
in the DNA structure of these genes in patients will provide more insight into this conundrum.   259 
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Furthermore the differences between mild/moderate and severe disease may be due to 260 
differences in strains of Acanthamoeba organism.  The majority of Acanthamoeba spp that 261 
cause keratitis are from the T4 group based on 18s RNA genotyping that separates strains 262 
into 17 evolutionary clades or groups (T1-T17). Preliminary information from one study 263 
indicates that strains with non-T4 genotypes may cause more severe disease,35 however, only 264 
three cases of non-T4 AK were compared to 14 T4 genotypes and confirmation in a larger 265 
study is required. As genetic profiling of Acanthamoeba spp. allows more refined typing, as 266 
can be seen by the mitochondrial cytochrome oxidase (Cox) gene sequencing,36 and greater 267 
number of cases are reported from other T strains37, 38 correlation between different strains 268 
and the outcomes of AK may be found.  Human biomarker profiling alongside in vitro and 269 
animal models will be key to future understanding of the interplay between the host immune 270 
system and organism virulence that is evidenced in some conditions such as malaria.39  271 
A limitation of the present study could be that AK cases were younger than controls. Tear 272 
investigations have generally been limited to normals or certain conditions affecting specific 273 
age groups and differences between normals across a range of ages has not been shown. 274 
Dry eye is more prevalent in older individuals, and increased levels of two cytokines measured 275 
in this study, IL-6 and IL-8 have been found in elevated levels in dry eye patients.21-24 The 276 
controls in this study, although older than the cases, were successful CL wearers, and are 277 
unlikely to have had significant dry eye disease. In any case, had some of the cases been on 278 
the dry eye spectrum, this would have only potentially masked greater differences in IL-8 levels 279 
and would not have affected the IL-6 results, in which only one control showed a reading 280 
above the detectable level.  281 
More daily disposable wearers were in the control group compared to AK patients in this study. 282 
This likely reflects the evidence that AK is more often a disease that occurs in reusable lens 283 
wearers, as the environmental contamination of lens cases supports the growth of 284 
Acanthamoeba spp.40 Only one study has evaluated the tear profile while wearing different 285 
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lens types; using lotrafilcon B (O2OPTIX; CIBA VISION, Duluth, Atlanta, GA) or senofilcon A 286 
(Acuvue Oasys; Johnson & Johnson Vision Care, Inc., Jacksonville, FL), no differences in 287 
levels on matrix metalloproteinase 9 (MMP-9), tissue inhibitor of metalloproteinases 1 (TIMP-288 
1)  and neutrophil gelatinase-associated lipocalin (NGAL)  during adapted daily wear were 289 
found.41 It is unlikely that even if lens wear type had an effect on tear cytokine/chemokine 290 
levels that this would confound results in the present study as all the AK patients and a 291 
proportion of the controls were not wearing lenses at the time of collection.   292 
 Another limitation of the study might be the time of the tear samples collection. The tear 293 
collection time was scheduled between 10am and 4pm to minimise possible diurnal effect and 294 
disruption to the MEH and IO clinics. While there are recent publications showing a diurnal 295 
change of certain tear cytokines and chemokines they indicate a difference between daytime 296 
and evening intervals (11am-1pm vs 5pm -7pm)42; 12am (midday) compared to 9-12pm 297 
(midnight).43 It is improbable that there would be a major variation in cytokine and chemokine 298 
levels during the 6-hour daytime interval in which we sampled tears.  299 
This study highlights key areas for future investigation of the pathogenesis of AK. We have 300 
shown that in a clinical setting, we can collect tears from patients with AK that may indicate 301 
the inflammatory status of the eye. Further investigation of cytokines not detected in this study, 302 
and other candidates in the pathways indicated by this analysis, may define a wider spectrum 303 
of cytokine changes. In association with careful tracking of patients during the disease 304 
process, we may be able to predict when the inflammatory status is changing. This information 305 
may help the clinician to better understand the clinical picture and make more informed 306 
decisions on individual AK patient management.  307 
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Table 1. Descriptive data of participants recruited for the study. 
 AK Cases (n=61) Controls (n=22) p value 
Age, years, mean (SD) 35.4 ±13.6 52.7±15.4 <0.001 
Gender, n (%) 
Males 
Females 
 
28 (45.9) 
33 (54.1) 
 
5 (22.7) 
17 (77.3) 
 
0.06 
Type of CL worn, n (% 
known) 
Daily soft 
2-4 weeks disposable soft 
>1 month replacement soft 
unknown 
 
9 (20.0) 
33 (73.3) 
3 (6.7) 
16  
 
14 (63.6) 
7 (31.8) 
1 (4.5) 
0 
0.02 
SD= standard deviation; CL= contact lens 
 
 
Table 1
Table 2. Proportion of non detectable samples for cases and controls. 
 AK Cases  Controls  
ND Analyte, n (%) 
IL-6 
IL-8 
IL-22 
IL-17E 
CXCL2 
IL-1 β 
IFNy 
Il-17F 
IL-17A 
IL-10 
IL-27 
 
 
104/120 (86.7) 
24/120 (20.0) 
74/120 (61.7) 
114/120 (95.0) 
11/69 (15.9) 
119/120 (99.2) 
120/120 (100) 
120/120 (100) 
120/120 (100) 
120/120 (100) 
120/120 (100) 
 
10/11 (90.9) 
7 /11 (63.6) 
7/11 (63.6) 
10/11 (90.9) 
3/11 (27.3) 
11/11 (100) 
11/11 (100) 
11/11 (100) 
11/11 (100) 
11/11 (100) 
11/11 (100) 
 
ND= non detectable 
 
Table 2
Table 3. Median concentrations and 95% confidence intervals (CI) for cytokines in tear 
samples of severe compared to mild-moderate cases. 
Cytokine 
Severe Mild-Moderate 
Z value 
n median 95% CI n median 95% CI 
IL-8 36 162.4 72.8-447.3 60 66.2 57.6-119.5 -2.31 
IL-22 22 470.8 313.5-1237.0 24 671.6 214.9-1501.0 -0.44 
IL-6 9 145.0 31.9-1361.5 7 80.9 16.8-391.0 1.27 
IL-17E 2 7265.1 N/A 4 2587.1 N/A -0.93 
CXCL2 22 3173.3 1150.9-4110.7 34 3007.2 1847.5-3703.9 -0.23 
n: number of samples; CI: confidence index; N/A: not applicable  
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